This would indicate that the increase in StO2 that is found via DRS in the MTD group (when compared to the CG group) through weeks 2 and 4 is the physiologically measurable outcome of the reduction in Vegf expression that starts at early at the beginning of the treatment phase, and that such increment in StO2 is likely to be driven by an alteration of the tumor vasculature due to therapy (an anti-angiogenic effect). This evidence concerns the gene VEGFA and neoplasm.